CIT-07 protocol
... The incidence and severity of AEs related to the immunosuppression including: allergy; reduction in GFR; increase in urinary albumin excretion; addition or intensification of anti-hypertensive therapy; addition or intensification of anti-hyperlipidemic therapy; oral ulcers; ...
... The incidence and severity of AEs related to the immunosuppression including: allergy; reduction in GFR; increase in urinary albumin excretion; addition or intensification of anti-hypertensive therapy; addition or intensification of anti-hyperlipidemic therapy; oral ulcers; ...
DT Adsorbed PI - VaccineShoppe.com
... Adsorbed at 2, 4, and 6 months of age, and acellular pertussis vaccine at 3, 5, and 7 months of age. One control group (N=85) received Diphtheria and Tetanus Toxoids Adsorbed concurrently at a separate site with acellular pertussis vaccine at 2, 4 and 6 months of age (data not shown). A second contr ...
... Adsorbed at 2, 4, and 6 months of age, and acellular pertussis vaccine at 3, 5, and 7 months of age. One control group (N=85) received Diphtheria and Tetanus Toxoids Adsorbed concurrently at a separate site with acellular pertussis vaccine at 2, 4 and 6 months of age (data not shown). A second contr ...
Evidence-Based Practice Guideline for the Management of Bronchiolitis in Infants and Children
... rooms, infants and children and any associated equipment or toys should be separated by at least two metres (a radius of one meter around each infant or child). ...
... rooms, infants and children and any associated equipment or toys should be separated by at least two metres (a radius of one meter around each infant or child). ...
Australian Public Assessment Report for Abatacept Proprietary Product Name: Orencia
... In contrast to mice and monkeys, unique target organ toxicities were evident in rats. Following up to three months exposure to abatacept in rats (both adult and juvenile), lymphocytic inflammation of the thyroid and pancreatic islets were evident. These findings are indicative of an autoimmune respo ...
... In contrast to mice and monkeys, unique target organ toxicities were evident in rats. Following up to three months exposure to abatacept in rats (both adult and juvenile), lymphocytic inflammation of the thyroid and pancreatic islets were evident. These findings are indicative of an autoimmune respo ...
Colloidal Submicron-Particle Curcumin Exhibits High Absorption
... system, bypassing the liver and “the first pass phenomenon” (16). Although BCM-95 and Theracurmin are micronized, the main differences are their solvents (BCM95: turmeric essential oil, Theracurmin: gum ghatti and glycerin). Moreover, the micronizing approach might be different. These differences ma ...
... system, bypassing the liver and “the first pass phenomenon” (16). Although BCM-95 and Theracurmin are micronized, the main differences are their solvents (BCM95: turmeric essential oil, Theracurmin: gum ghatti and glycerin). Moreover, the micronizing approach might be different. These differences ma ...
Nystatin - E
... significant differences between the groups. All patients had positive cultures for C. albicans before treatment. Patients received either qid or tid dosage and the average length of therapy was 5.7 and 6.3 days respectively. On the 5th day, 18 of the placebo patients and 4 of the nystatin group were ...
... significant differences between the groups. All patients had positive cultures for C. albicans before treatment. Patients received either qid or tid dosage and the average length of therapy was 5.7 and 6.3 days respectively. On the 5th day, 18 of the placebo patients and 4 of the nystatin group were ...
Product Monograph - Paladin Labs Inc.
... Interactions between GlucaGen® (glucagon) and other drugs are not known, when GlucaGen® is used in diabetes. Published literature has shown the following interactions: Insulin: Reacts antagonistically towards glucagon (12). Indomethacin: Glucagon may lose its ability to raise blood glucose or parado ...
... Interactions between GlucaGen® (glucagon) and other drugs are not known, when GlucaGen® is used in diabetes. Published literature has shown the following interactions: Insulin: Reacts antagonistically towards glucagon (12). Indomethacin: Glucagon may lose its ability to raise blood glucose or parado ...
Endovascular Radiofrequency Ablation for Varicose Veins
... About the Ontario Health Technology Assessment Series To conduct its comprehensive analyses, the Medical Advisory Secretariat systematically reviews available scientific literature, collaborates with partners across relevant government branches, and consults with clinical and other external experts ...
... About the Ontario Health Technology Assessment Series To conduct its comprehensive analyses, the Medical Advisory Secretariat systematically reviews available scientific literature, collaborates with partners across relevant government branches, and consults with clinical and other external experts ...
Stockley`s Herbal Medicine`s Interactions
... This first edition of Stockley’s Herbal Medicines Interactions is an exciting new addition to the Stockley family of products, and one that has been several years in the planning and execution. When researching Stockley’s Drug Interactions we had noticed the growing wealth of experimental data on he ...
... This first edition of Stockley’s Herbal Medicines Interactions is an exciting new addition to the Stockley family of products, and one that has been several years in the planning and execution. When researching Stockley’s Drug Interactions we had noticed the growing wealth of experimental data on he ...
CURRICULUM VITAE - Oregon Medical Research Center
... Principal Investigator for OHSU study #4499, "Phase 2A randomized, double-blind, vehicle-controlled, intra-individual comparison trial assessing safety, toleration, pharmacokinetics and pilot efficacy of 4 weeks treatment with CP-690,550 in chronic plaque psoriasis" Principal Investigator for OHSU s ...
... Principal Investigator for OHSU study #4499, "Phase 2A randomized, double-blind, vehicle-controlled, intra-individual comparison trial assessing safety, toleration, pharmacokinetics and pilot efficacy of 4 weeks treatment with CP-690,550 in chronic plaque psoriasis" Principal Investigator for OHSU s ...
St John`s wort (Hypericum perforatum L.): a review of its
... antidepressants, particularly newer antidepressant agents, such as the selective serotonin reuptake inhibitors (recent comparative studies with fluoxetine and sertraline have been conducted). Also, there is a need for further studies in well-defined groups of patients, in different types of depressi ...
... antidepressants, particularly newer antidepressant agents, such as the selective serotonin reuptake inhibitors (recent comparative studies with fluoxetine and sertraline have been conducted). Also, there is a need for further studies in well-defined groups of patients, in different types of depressi ...
In February 2013, GlaxoSmithKline (GSK)
... visit before the start of any add-on lipid-lowering medication. All tests of significance, unless otherwise stated, were performed at a significance level of alpha=0.05, two-sided. Unless otherwise noted, continuous variables were summarized descriptively using number of subjects (n), mean, standard ...
... visit before the start of any add-on lipid-lowering medication. All tests of significance, unless otherwise stated, were performed at a significance level of alpha=0.05, two-sided. Unless otherwise noted, continuous variables were summarized descriptively using number of subjects (n), mean, standard ...
Abstracts of the 19th Cochrane Colloquium
... Methods: Using the publications of the GRADE Group as a starting ...
... Methods: Using the publications of the GRADE Group as a starting ...
HIGHLIGHTS OF PRESCRIBING INFORMATION because of risk of overdose. (5.3) Candida albicans
... LABA, such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-r ...
... LABA, such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-r ...
PREZISTA® (darunavir) oral suspension PREZISTA® (darunavir
... treatment-naïve subjects 12 to less than 18 years of age and pharmacokinetic modeling and simulation for patients 3 to less than 12 years of age. In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with PREZISTA/ritonavir: • Treat ...
... treatment-naïve subjects 12 to less than 18 years of age and pharmacokinetic modeling and simulation for patients 3 to less than 12 years of age. In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with PREZISTA/ritonavir: • Treat ...
ABC Clinical Guide 2003 - American Botanical Council
... bedtime, with an earlier dose in the evening, if necessary (ESCOP, 1997). For adults, the dose should be in proportion to body weight; use as a tea infusion or dry extract. Children from 3–12 years old should use valerian only under medical supervision (ESCOP, 1997). ...
... bedtime, with an earlier dose in the evening, if necessary (ESCOP, 1997). For adults, the dose should be in proportion to body weight; use as a tea infusion or dry extract. Children from 3–12 years old should use valerian only under medical supervision (ESCOP, 1997). ...
content outline - The American Board of Pediatrics
... a. Know the differences in the composition of DT and dT b. Plan the administration of DT or dT based on the age of the patient 7. Pertussis vaccines (whole-cell and acellular) a. Understand the difference between the whole-cell and acellular pertussis vaccines b. Know the indications, contraindicati ...
... a. Know the differences in the composition of DT and dT b. Plan the administration of DT or dT based on the age of the patient 7. Pertussis vaccines (whole-cell and acellular) a. Understand the difference between the whole-cell and acellular pertussis vaccines b. Know the indications, contraindicati ...
FATE THERAPEUTICS INC (Form: 10-K, Received
... We plan to continue the validation of our two platforms by demonstrating the clinical benefit of our initial product candidates over the next two years in three orphan disease settings: hematologic malignancies, LSDs and muscular dystrophy. Our lead product candidate from our HSC modulation platform ...
... We plan to continue the validation of our two platforms by demonstrating the clinical benefit of our initial product candidates over the next two years in three orphan disease settings: hematologic malignancies, LSDs and muscular dystrophy. Our lead product candidate from our HSC modulation platform ...
The Placebo Effect (A comprehensive Review of the Placebo Effect
... (ketorolac, metamizol) medications across hidden versus open intravenous injections in patients with postoperative pain. (Data are from Amanzio et al. 2001.) ...
... (ketorolac, metamizol) medications across hidden versus open intravenous injections in patients with postoperative pain. (Data are from Amanzio et al. 2001.) ...
NBA - The Criteria for the clinical use of intravenous immunoglobulin
... to provide information about criteria for accessing intravenous immunoglobulin funded under the National Blood Arrangements. Any advice relating to other forms of treatment relevant to the conditions in The Criteria for the clinical use of intravenous immunoglobulin in Australia (the Criteria) have ...
... to provide information about criteria for accessing intravenous immunoglobulin funded under the National Blood Arrangements. Any advice relating to other forms of treatment relevant to the conditions in The Criteria for the clinical use of intravenous immunoglobulin in Australia (the Criteria) have ...
scientific framework of homeopathy
... Association (Ordre National des Me´decins) recognised homeopathy as an existing therapeutic medical method and stated that homeopathic education should be installed at Universities. Further, a subspecialty under the term of “certificate of capacity in homeopathy” has been in place in Switzerland sin ...
... Association (Ordre National des Me´decins) recognised homeopathy as an existing therapeutic medical method and stated that homeopathic education should be installed at Universities. Further, a subspecialty under the term of “certificate of capacity in homeopathy” has been in place in Switzerland sin ...
Medicare Benefits Schedule Review Taskforce Report from the
... target its use to diagnose asthma and chronic obstructive pulmonary disease (COPD). It is recommended that the item be available once a year and that the fee and rebate be doubled to $40 to encourage use in primary care. ...
... target its use to diagnose asthma and chronic obstructive pulmonary disease (COPD). It is recommended that the item be available once a year and that the fee and rebate be doubled to $40 to encourage use in primary care. ...
Salmeterol + Fluticasone propionate
... challenges conducted approximately 8.5 hours post-dose, was significantly less in the combination therapy group when compared to the FP group in the ITT population. No new safety signal was detected. Assessor’s comment: This study showed that bronchoprotection measured as the percent fall in FEV1 af ...
... challenges conducted approximately 8.5 hours post-dose, was significantly less in the combination therapy group when compared to the FP group in the ITT population. No new safety signal was detected. Assessor’s comment: This study showed that bronchoprotection measured as the percent fall in FEV1 af ...
Report on the Deliberation Results August 25, 2009 Evaluation and
... The efficacy of the product has been shown in phase III clinical studies (P054, P055, ONO-5435-08 to -10) etc. No major safety problems have been identified in phase III clinical studies etc. Cardiovascular events and tumor development etc. during long-term use and the safety in patients with modera ...
... The efficacy of the product has been shown in phase III clinical studies (P054, P055, ONO-5435-08 to -10) etc. No major safety problems have been identified in phase III clinical studies etc. Cardiovascular events and tumor development etc. during long-term use and the safety in patients with modera ...
OSSIE Guide to Clinical Handover Improvement
... support the process. Further work was then required to ensure the safe and effective use of this new feature of the handover process. ...
... support the process. Further work was then required to ensure the safe and effective use of this new feature of the handover process. ...